Itama Ranoraya

Itama Ranoraya

IRRA · JK · Healthcare / Medical Distribution

360.00IDR+8.00 (+2.27%)

Price History

Full chart

Market Stats

Previous Close352.00
Open350.00
Day Range346.00 – 364.00
52-Week Range322.00 – 615.00
Volume1.82M
Market Cap542.81B
P/E (TTM)8.47
Forward P/E0.00
EPS42.48
Dividend Yield0.00%
Beta0.41
50-Day Avg370.16
200-Day Avg390.02

About

PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. It offers in vitro diagnostics products comprising rapid test, serology, glucose diagnostic, NAPZA test, and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; nefrology, blood and transfusion, orthopedic, radiotherapy, and surgical products; and hospital supplies and hospital kitchen equipment. The company also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, it leases office space. It sells its products under the oneject, Abbott, Terumo, DIRUI, Medtronic, mindray, ZOLL, Sansin, Vestfrost, ASCENSIA, Hemocue, CUREXO, SATInc., PT. MEGA, Planmed, Sinmed, Balmed, KSM CARE, Trisan Care, Shamrock, OTORO, GEA, Hologic, IS, Avimac, RadmediX, and SMAM brand names. The company was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk operates as a subsidiary of PT Global Dinamika Kencana.

Company Details

  • SectorHealthcare
  • IndustryMedical Distribution
  • CEOMr. Heru Firdausi Syarif
  • Employees232
  • HeadquartersMT. Haryono Square Lt. 1, Jakarta Timur, Indonesia, 13330, Indonesia
  • Websitehttps://www.itama.co.id

Leadership

  • Mr. Heru Firdausi SyarifPresident Director · b. 1966
  • Mr. Hendry HermanSales Director & Director · b. 1982
  • Roben PontinusHead of Internal Audit
  • Mr. Nanan Meinanta LasahidoCorporate Secretary & Director · b. 1964
  • Viertin Maretson Lumban TobingCorporate Secretary & Director

Financials

Income Statement

Currency: IDR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue12.99B225.20B265.63B281.75B563.89B1.32T753.57B696.30B977.49B1.10T
Growth (%)-+1633.46%+17.95%+6.07%+100.14%+134.04%-42.90%-7.60%+40.38%+12.55%
Cost of Revenue10.30B181.08B209.61B222.16B443.47B1.08T594.36B569.24B767.43B856.15B
Gross Profit2.69B44.13B56.02B59.59B120.42B236.02B159.21B127.06B210.06B244.06B
Gross Margin20.72%19.59%21.09%21.15%21.36%17.88%21.13%18.25%21.49%22.18%
Operating Expense1.58B8.14B12.92B16.19B42.22B92.07B84.15B100.27B117.93B143.38B
Operating Income1.11B35.99B43.10B43.40B78.20B143.95B75.06B26.79B92.13B100.68B
Operating Margin8.58%15.98%16.23%15.40%13.87%10.91%9.96%3.85%9.42%9.15%
EBITDA1.37B33.42B44.74B46.12B82.07B156.88B78.97B31.28B103.51B115.17B
EBITDA Margin10.52%14.84%16.84%16.37%14.55%11.89%10.48%4.49%10.59%10.47%
Net Income706.71M23.98B32.26B33.21B60.52B112.16B48.00B5.20B53.26B65.53B
Net Income Margin5.44%10.65%12.15%11.79%10.73%8.50%6.37%0.75%5.45%5.96%
Interest Expense241.08M52.77M150.55M552.64M1.49B4.95B8.93B16.50B25.52B36.15B
Interest Expense % of Total Revenue1.86%0.02%0.06%0.20%0.26%0.37%1.19%2.37%2.61%3.29%

Balance Sheet

Currency: IDR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.20B127.67B136.26B325.43B535.27B782.04B733.93B1.06T1.66T2.43T
Total Liabilities16.42B83.32B69.62B90.26B292.94B279.99B249.88B599.69B1.15T1.86T
Total Equity10.78B44.35B66.64B235.17B242.33B502.05B484.04B459.20B512.31B577.83B
Cash13.29B50.36B20.17B42.86B233.04B135.29B116.78B92.03B27.33B80.13B
Total Debt2.67B1.43B4.84B-482.51M80.00B160.21B240.86B619.84B835.92B
Net Debt-10.62B-48.93B-15.33B-42.86B-232.55B-55.29B43.42B148.83B592.51B755.78B

Cash Flow

Currency: IDR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.06B31.51B-9.25B-8.18B147.09B-106.83B55.61B-37.63B-430.13B-110.49B
Investing Cash Flow10.59B-3.40B-14.36B-4.57B-9.84B-218.25B-4.00B-35.05B6.69B-43.61B
Financing Cash Flow-6.73B8.96B-6.58B35.43B52.92B227.34B14.41B48.45B358.98B206.91B
Capital Expenditure11.98M4.80B7.76B4.91B12.64B20.04B4.44B34.80B25.66B53.43B
Free Cash Flow1.05B26.71B-17.01B-13.09B134.44B-126.87B51.17B-72.43B-456.03B-163.92B
Dividends Paid10.00B10.00B10.00B45.00B9.34B18.00B29.30B0--
FCF to OCF98.87%84.77%183.94%160.01%91.40%118.76%92.02%192.49%106.02%148.35%
Dividend Paid to FCF949.69%37.43%-58.80%-343.79%6.95%-14.19%57.25%0.00%--

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-------------
EPS Actual1.405.0317.3416.7013.9419.8922.7917.2013.629.243.014.814.14
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap542.81B
Enterprise Value1.60T
Trailing P/E8.47
Forward P/E0.00
Price / Sales0.52
Price / Book0.90
EPS42.48
Book Value400.90
Revenue (TTM)1.05T
Gross Profit (TTM)260.70B
EBITDA116.78B
Profit Margin6.26%
Operating Margin8.94%
Return on Equity11.47%
Return on Assets2.63%
Shares Outstanding1.51B
Shares Float247.12M
Beta0.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
18.75Aug 9, 2022
20211×
12.00May 3, 2021
20201×
6.00Apr 9, 2020